**Case 16**
A 30 year-old Thai female from Bangkok.

**Chief complaint:** Indurated plaques with reddish-brown papules on extremities for 5 months

**Present illness:**
5 months previously, she noticed slow progressive asymptomatic subcutaneous rash with scattered reddish-brown papules on both legs and right arm. She denied fever, weight loss, arthralgia, and other systemic symptoms.

**Past history:**
- No previous significant underlying disease.
- No history of contact TB patient.
- Current medication: oral contraceptive pill.

**Physical examination:**
- V/S: T 37.2°C, PR 70/min, RR 16/min, BP 100/60 mmHg
- HEENT: not pale, anicteric sclerae
- Lymph node: no lymphadenopathy
- CVS: normal s1s2, no murmur
- RS: normal chest contour, normal breath sound
- Abdomen: soft, no hepatosplenomegaly

**Skin examination:**
- Multiple brownish indurated plaques overlying with discrete reddish-brown papules on right arm, both inner thighs and legs.
**Histopathology:** (S16-8268A, right arm)

- Dense nodular and diffuse inflammatory-cell infiltrate of giant epithelioid histiocytes, with abundant pale eosinophilic cytoplasm and vesicular nuclei admixed with numerous lymphocytes, some plasma cells and a few eosinophils, in the deep dermis and subcutaneous tissue
  - Some intact lymphocytes present within cytoplasm of histiocytes ("emperipolesis")

**Immunohistochemistry:** positive S100, scattered positive CD68, negative CD1a

**Diagnosis:** Cutaneous Rosai-Dorfman disease

**Investigation:**
- CBC: Hb 11.9 g/dL, Hct 35.9 %, WBC 8,600/cumm (N 75%, L 21%, Mono 3%, Eo1%), MCV 100.8 um³, Platelet 344,000/cumm
- Cr 0.52 mg/dL
- LFT: normal
- ANA, Anti-dsDNA: negative

**Treatment:**
- Prednisolone 30 mg/day for 1 month then taper to 15 mg/day

**Presenter:** Panadda Darukarnphut, MD
**Consultant:** Ruedee Phasukthaworn, MD

**Discussion:**
Rosai-Dorfman disease (RDD) or sinus histiocytosis with massive lymphadenopathy (SHML) is a rare benign disorder of histiocytic proliferation. It was first described in 1969 by Rosai and Dorfman. Typically, RDD manifests in the second and third decades of life. African Americans are more often affected than Caucasians and a male predominance is present.¹ The etiology is remain
unknown, but two hypotheses have been proposed as follows: a disturbance of cell-mediated immunity and infectious agents including Epstein-Barr virus, human herpesvirus six, parvovirus B19, herpes simplex virus, Brucella, Klebsiella rhinoscleromatis and Nocardia. RDD was characterized by extensive cervical lymphadenopathy associated with fever, polyclonal gammopathy, and leukocytosis with neutrophilia. Lymphadenopathy appears in 87% of the patients and is often cervical, bilateral, massive and painless. Inguinal (25.6%), axillary (23.7%) and mediastinal lymph nodes (14.5%) may also be involved. Extranodal manifestations have been reported in 43% of cases. The most commonly involved extranodal sites include the skin, CNS, orbit and eyelid, upper respiratory tract, and less commonly, the gastrointestinal tract. Cutaneous manifestations are varied and appear as single or multiple macules, papules, plaques or nodules, with colors ranging from red-brown to yellow. The cutaneous-only form of RDD (CRDD) is rare accounting for only 3% of reported RDD cases. A clinically distinct entity from RDD. Women with CRDD appear to be more affected than men, and most cases have been seen among Caucasian and Asian populations. In CRDD, patients typically present with normal laboratory data and no adenopathy. Lesions can vary, ranging from less than 1 cm to 30 cm or more at their greatest dimensions. Clinically, CRDD usually presents as erythematous or brownish infiltrated nodules or plaques with surrounding satellite papules. On dermoscopy, lesions classically resemble ovoid structures on an erythematous base with multiple yellowish structures in the periphery. The most common site of skin involvement is the extremities followed by the head and neck region. Most patients with CRDD are benign clinical course, with a frequent and spontaneous resolution of lesions.

The diagnosis of RDD is based on the correlation of clinical, serological, and histopathological findings to exclude other causes. The classic histopathology of RDD and CRDD includes dense diffuse or nodular infiltrates of foamy histiocytes mixed with lymphocytes and plasma cells exhibiting emperiplois. In extranodal RDD, increased amounts of fibrosis and fewer histiocytes are present in the lesions as compared with nodal RDD. Immunohistochemical testing shows strong and consistent positivity for S-100 protein and for CD68, but not for CD 1a. The laboratory investigation for RDD should include rheumatoid factor, antinuclear antibody test, complete blood counts, liver and kidney function tests, immunoglobulin levels, and an erythrocyte sedimentation rate (ESR), screening for EBV, cytomegalovirus, HHV-6, HHV-8, and HIV. Imaging such as computed tomography (CT) scans of the neck, chest, abdomen, and pelvis to look for distant disease. The role of bone marrow biopsy is unclear, it is usually obtained because primary bone marrow disorders are included in the differential diagnosis of RDD.

There is no standard treatment for RDD due to benign clinical course and usually spontaneous resolving over 1–3 year. The treatment options include topical/ intralesional/ systemic glucocorticoids, acitretin, isotretinoin, dapsone, thalidomide, cytotoxic chemotherapy (eg. vincristine, vinblastine, methotrexate), interferon-α radiotherapy, pulsed dye laser and surgical excision.

In summary, we present a case of middle age female who presented with indurated plaques and reddish-brown papules on the extremities for 5 months. The clinical and histopathological findings suggest the diagnosis of cutaneous Rosai-Dorfman disease. She was treated by oral prednisolone 30 mg/day for 1 month and then tapered to 15 mg/day with partial improvement.
References


